Drug Development for Transthyretin Amyloidosis: Time to Fix the System?

JACC Case Rep. 2024 Aug 7;29(15):102414. doi: 10.1016/j.jaccas.2024.102414.

Authors

Nowell M Fine¹, Ronald M Witteles²

Affiliations

¹ Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
² Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California, USA.

No abstract available

Keywords: ATTR amyloidosis; clinical trials; drug development; study outcomes.

Publication types

Editorial